Literature DB >> 26766803

Sexuality and erectile function after implantation of an Adjustable Transobturator Male System (ATOMS) for urinary stress incontinence. A multi-institutional prospective study.

Alexander Friedl1, Wilhelm Bauer, Maximilian Rom, Danijel Kivaranovic, Werner Lüftenegger, Clemens Brössner.   

Abstract

OBJECTIVES: To investigate erectile function and sexuality before/after implantation of the ATOMS device including continence outcome, pain perception and co-morbidities.
MATERIALS AND METHODS: We collected data from 34 patients (2010-2014) who were provided with an ATOMS implant due to mild or moderate stress urinary incontinence (SUI) after radical prostatectomy (RPE), transurethral resection (TURP) or radiotherapy. Previous failed implants were no contraindication. Sexuality was evaluated with the International Index of Erectile Function (IIEF-5). The Visual Analog Scale (VAS) and Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) were used to analyse pain perception. Results regarding continence, influence of co-morbidities and drug intake were interpreted.
RESULTS: IIEF-5 score increased 6 months after ATOMS implantation with a mean difference of 2.18 (Cl: 1.22, 3.14), p < 0,001). Non-sexually active patients had the greatest benefit. However, 50% of patients achieved a mean IIEF-5 of 10.1 and 38% of patients reported a new onset of sexual activity at follow up (mean IIEF-5 score of 12.9). This is in accordance with reduced SUI and absence of persistent pain syndrome. Overall success rate regarding 24h pad-use was 88% (no pad rate 38%). Previous failed implants did not influence results but diabetes, obesity and drug intake (beta-blockers, antidepressants) led to poorer outcomes.
CONCLUSION: Sexuality and erectile function improves significantly 6 months after ATOMS implantation. We postulate that reduced SUI (also during sexual activity) and absence of chronic pain are the improving factors. ATOMS should be offered to men with mild to moderate SUI who are interested in regaining their erectile function and sexual activity.

Entities:  

Mesh:

Year:  2016        PMID: 26766803     DOI: 10.4081/aiua.2015.4.306

Source DB:  PubMed          Journal:  Arch Ital Urol Androl        ISSN: 1124-3562


  6 in total

1.  Systematic review and meta-analysis comparing Adjustable Transobturator Male System (ATOMS) and male Readjustment Mechanical External (REMEEX) system for post-prostatectomy incontinence.

Authors:  Javier C Angulo; Sonia Ruiz; Martín Lozano; Ignacio Arance; Miguel Virseda; David Lora
Journal:  World J Urol       Date:  2020-06-11       Impact factor: 4.226

Review 2.  Review of surgical implant procedures for male incontinence after radical prostatectomy according to IDEAL framework.

Authors:  Dimitri Barski; Holger Gerullis; Thomas Otto
Journal:  Updates Surg       Date:  2017-05-06

3.  Implant of ATOMS® system for the treatment of postoperative male stress urinary incontinence: results of a single centre.

Authors:  Alessandro Giammò; Enrico Ammirati; Annarita Tullio; Gianni Bodo; Alberto Manassero; Paolo Gontero; Roberto Carone
Journal:  Int Braz J Urol       Date:  2019 Jan-Feb       Impact factor: 1.541

4.  Effectiveness of Adjustable Transobturator Male System (ATOMS) to Treat Male Stress Incontinence: A Systematic Review and Meta-Analysis.

Authors:  Cristina Esquinas; Javier C Angulo
Journal:  Adv Ther       Date:  2018-12-17       Impact factor: 3.845

Review 5.  Adjustable sling for the treatment of post-prostatectomy urinary incontinence: systematic review and meta-analysis.

Authors:  Laercio Antonio da Silva; Rogério Simonetti; Edina Mariko Koga da Silva
Journal:  Einstein (Sao Paulo)       Date:  2019-09-23

6.  Systematic review and meta-analysis comparing Adjustable Transobturator Male System (ATOMS) and Adjustable Continence Therapy (ProACT) for male stress incontinence.

Authors:  Javier C Angulo; Sandra Schönburg; Alessandro Giammò; Francisco J Abellán; Ignacio Arance; David Lora
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.